Client Alert – Mexico Issues New Implementing Regulations for the Federal Law on Industrial Property Protection: What Businesses Need to Know

Introduction

On April 28, 2026, the Mexican Federal Executive published the long-awaited Regulation (Reglamento) implementing the Ley Federal de Protección a la Propiedad Industrial (the “LFPPI” or “Law”), Mexico’s comprehensive industrial property statute. Signed by President Claudia Sheinbaum Pardo and published in the Diario Oficial de la Federación (evening edition), this new Regulation replaces the prior regulations issued on November 23, 1994, and all subsequent amendments, effectively closing a regulatory gap that had existed since the LFPPI came into force. The Regulation will enter into force sixty business days after its official publication.

For businesses operating in or expanding into Mexico, the new Regulation introduces critical procedural and substantive changes affecting patent prosecution, trademark registration, licensing, franchise arrangements, technology transfer, and enforcement—all of which deserve close attention.

Key Regulatory Changes:

Digitalization of IP Proceedings and Electronic Filing. One of the most significant modernizations in the new Regulation is the comprehensive framework for electronic submissions and digital proceedings before the Mexican Institute of Industrial Property (“IMPI”). The Regulation authorizes IMPI to recognize any electronic signature that complies with applicable law, by means of an administrative Acuerdo. Applications and filings may now be submitted electronically, subject to IMPI’s technical requirements. Electronic notifications will take effect on the day the user accesses the electronic system; if the electronic notification board is not consulted on the 15th and last day of each month, notification is deemed to have been made the following business day. Electronic copies and certifications issued by IMPI will carry the same evidentiary value as their physical counterparts.

Online Infringement Proceedings. The Regulation creates an entirely new Chapter VII establishing a procedure for administrative infringement declarations to be conducted online (procedimiento en línea), through IMPI’s electronic services. All filings, evidence, orders, and resolutions will form part of an electronic file, and documents submitted with an advanced electronic signature will have the same legal and evidentiary effects as autograph-signed documents. Notably, the online infringement procedure will not take effect immediately upon the Regulation’s entry into force; instead, it will become operational the day after IMPI publishes a specific implementing Acuerdo, which must be issued within eighteen months of the Regulation’s effective date.

Technology Transfer Registry. In an entirely new development, Chapter IX of the Regulation establishes a Technology Transfer Registry (Registro de Transferencia de Tecnología) administered by IMPI. This Registry covers the inscription of license agreements, IP rights assignments, confidentiality agreements, collaboration and research agreements, consulting and sponsorship agreements, material transfer agreements, joint ventures, academic spin-offs, research-based startups, and any other instrument involving the transfer of technology or knowledge where the parties seek enforceability against third parties. Critically, registration is not a validity requirement for these instruments; rather, it is a condition for enforceability against third parties (oponibilidad frente a terceros), and the absence of registration does not affect the agreement’s effectiveness between the parties. Registered instruments will have a public version disclosing the legal nature of the agreement, party identification, IP rights involved, term, and applicable territory. IMPI will also develop catalogs of freely available technologies in Mexico and of technologies whose holders request publicity to facilitate transfer.

Alternative Dispute Resolution Mechanisms. Chapter X introduces a formal framework for conciliation and alternative dispute resolution within IMPI’s administrative infringement proceedings. IMPI may promote conciliatory resolution at any stage of an administrative proceeding prior to a final resolution, provided that third-party rights and public policy are not affected. The ADR process is governed by principles of voluntariness, confidentiality, good faith, legality, impartiality, equity, flexibility, and party autonomy. Conciliation sessions may take place in person or through videoconference and secure digital platforms. A resulting settlement agreement must be signed by the parties and the designated facilitator, and once ratified by the competent authority, it will have the binding force of an administrative cosa juzgada. When the settlement involves the modification, assignment, or extinction of IP rights, it must be recorded in the corresponding registries. Pending administrative proceedings at the time the Regulation enters into force may also access ADR mechanisms.

Enhanced Patent Provisions. The Regulation addresses several important patent prosecution matters connected to the LFPPI amendments. It codifies rules for provisional patent applications, including payment requirements and content alignment between the provisional and formal applications. The Regulation also details the procedure for patent term adjustments, defining what constitutes “reasonable delays” for purposes of Article 132 of the Law, including the eighteen-month and two-month periods provided by Articles 107 and 109 of the LFPPI, as well as the time between the expiration of those periods and IMPI’s first substantive examination action. A new mandatory resolution procedure (Chapter VIII) enables applicants to request binding resolutions when IMPI has failed to issue a definitive decision within the statutory timeframe, with detailed rules on the computation of excluded periods.

Genetic Resources and Traditional Knowledge Disclosure. Consistent with the LFPPI’s requirements, the Regulation requires patent applicants to disclose the country of origin or source of genetic resources, or the indigenous peoples or local communities that provided traditional knowledge, when the invention is based on such resources and could not have been made without them. If this information is omitted during substantive examination, IMPI will require its correction within two months.

Pharmaceutical Patent Listings. The Regulation addresses the pharmaceutical patent listing (linkage list) referenced in Article 162 of the LFPPI, requiring that listed patents specify the patent term, the correspondence between the generic denomination and pharmaceutical identity of the active ingredient, and the nomenclature conforming to internationally recognized naming conventions. Patents covering processes are excluded from the listing.

Trademarks, Franchises, and Licensing. The Regulation provides detailed requirements for trademark representation, classification under the Nice Agreement, and brand coexistence through written consent mechanisms. For franchise arrangements, it substantially details the pre-contractual disclosure obligations owed to prospective franchisees, including information about the franchisor’s identity, franchise description, seniority, IP rights involved, payment amounts, technical assistance, territorial scope, sub-franchising rights, confidentiality obligations, master franchise arrangements, investment return estimates, and operational data. Licensed or franchised products must indicate the name and address of both the trademark owner and the licensee or franchisee, as well as a statement that use is under a registered trademark license.

Denominations of Origin and Geographical Indications. The Regulation provides a detailed framework for the protection and administration of denominations of origin and geographical indications, including requirements for maintaining the geographic link, rules on generic terms, provisions for coexistence of identical or confusingly similar names, and the procedure for recognizing foreign designations in Mexico. Authorized users must display the legend “Denominación de Origen Protegida” or “Indicación Geográfica Protegida” (or their abbreviations “D.O.P.” or “I.G.P.”) on their labeling.

Enforcement and Provisional Measures. The Regulation modernizes enforcement mechanisms to address digital infringement. It explicitly contemplates inspections of virtual or electronic establishments, digital platforms, profiles, and accounts. Provisional measures now include the ability to block virtual, digital, or electronic media, with the possibility of total blocking when the alleged infringer cannot be located. The Regulation also establishes a framework for suspending the free circulation of goods in coordination with customs authorities. Fines are calculated based on the Unidad de Medida y Actualización as of the date of the infringement.

Compliance Programs and Social Outreach. IMPI is empowered to implement social-impact work programs to promote IP protection in underserved regions, including differentiated tariffs. Entities that certify having trained all their personnel on IP regulatory compliance may receive an official compliance badge (distintivo).

Practical Implications for Clients

The new Regulation has several direct and actionable implications for businesses with IP interests in Mexico.

First, companies should review existing technology transfer, licensing, and collaboration agreements to determine whether registration in the new Technology Transfer Registry is advisable, particularly if enforceability against third parties is a strategic priority. While registration is not a validity condition, its absence limits the agreement’s reach to the contracting parties alone.

Second, businesses should prepare for the transition to electronic filings and digital proceedings. Obtaining recognized electronic signatures and establishing internal workflows for electronic case management before IMPI will be essential as the system becomes fully operational.

Third, the availability of alternative dispute resolution within IMPI administrative proceedings—including for pending cases—offers a potentially faster and more cost-effective path to resolving IP disputes. Companies engaged in active infringement proceedings should evaluate whether conciliation may be advantageous.

Fourth, patent applicants in the pharmaceutical and biotechnology sectors should pay particular attention to the new genetic resource and traditional knowledge disclosure requirements, as well as the updated pharmaceutical patent listing rules, as non-compliance could result in costly delays.

Fifth, franchisors and licensors operating in Mexico should audit their disclosure practices and commercial labeling to ensure alignment with the expanded pre-contractual information requirements and mandatory product legends.

Finally, brand owners enforcing rights against digital infringement should take note of IMPI’s expanded powers to inspect virtual establishments and order the blocking of digital channels and platforms, which represent a significant strengthening of the enforcement toolkit.

Because the Regulation will take effect sixty business days after April 28, 2026, affected parties have a window to prepare, but that window is finite. The prior 1994 regulations are abrogated as of the effective date, and matters already in progress will continue under the rules applicable at the time of filing.

FisherBroyles Perspective

This new Regulation represents a landmark overhaul of Mexico’s industrial property procedural framework, the first comprehensive update in over three decades. It signals Mexico’s commitment to modernizing its IP administration in line with international standards, while simultaneously creating new tools for technology transfer, digital enforcement, and alternative dispute resolution. For multinational companies and domestic enterprises alike, the breadth of these changes demands proactive assessment and planning.

 

 

For additional information, please contact:

Sergio Legorreta at [email protected] with any questions or more specific situations.

 

FisherBroyles is an international law firm practicing in a number of jurisdictions both in the United States and overseas through affiliated legal entities and branch offices of those entities.  Legal services in Mexico are provided through Bravo Gutierrez & Münch, S.C., a member of FisherBroyles (the “Contracting Member”), with offices located in Mexico City, at Parque Lincoln, 5th Floor, Aristoteles 77, Polanco, Mexico City, Ciudad de Mexico 11560 and in Monterrey, at Blvd. Antonio L. Rodriguez 3000-5to piso Interior, 501 Torre Albia, Col. Santa Maria 64650 Monterrey, N.L.

The FisherBroyles Members engage in coordinated international legal practice and may share certain support services but are separate legal entities, each of which is solely responsible for its own work and is not responsible for the work of any other FisherBroyles Member.  Each FisherBroyles Member is subject to the laws and regulations of the particular jurisdiction or jurisdictions in which it operates. Full details of the legal and regulatory status of each FisherBroyles Member are available on the FisherBroyles website.

The use of the name FisherBroyles is for description purposes only and does not imply that the Member Firms are in a partnership or are part of an LLP.  The use of the word “partner” on any Member Firm’s website or in any other Member Firm materials refers to a partner or member of a FisherBroyles Member or an employee or consultant with equivalent standing and qualifications.  You agree that your relationship is with the Contracting Member and not with another FisherBroyles Member unless otherwise confirmed in writing to you. You also agree that your relationship is not with any individual who is a member, employee, or consultant (including anyone we call a partner) of the Contracting Firm Member, who will therefore assume, to the extent permitted by law, no personal liability to you.  Absent the explicit agreement and consent of both entities involved, no FisherBroyles Member is responsible for the acts or omissions of, nor has any authority to obligate or otherwise bind, any other FisherBroyles Member.